Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Investor Presentation
Q1 FY27
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY24
Investor Presentation
Q3 FY24
Investor Presentation
Q2 FY24
Investor Presentation
Q4 FY23
Investor Presentation
Q3 FY21
Sanofi India Ltd (SANOFI) is currently trading at 3,130.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sanofi India Limited is a listed pharmaceutical company focused on manufacturing and marketing prescription medicines in India, with a strategic emphasis on diabetes care (insulin portfolio) and distribution partnerships for cardiovascular, CNS and oral anti‑diabetic categories; it operates manufacturing sites (notably Goa) and sells through independent distributors across domestic and select export markets. The company completed a pivotal transformation in 2025: refocusing on insulin, launching a partnership model for legacy brands, and reorganizing around digital and AI‑enabled customer engagement, which management cites as the foundation for sustainable, profitable growth even as transitional effects impacted reported revenue and segmental comparability. Financially the year shows mixed signals: domestic sales were essentially flat (+1% FY), diabetes insulin domestic volumes grew +6% and Q4 diabetes grew +11%, but exports plunged (-40% FY) driven by Ankleshwar divestment and partnership phasing, while operating expenses were cut ~17% year‑on‑year supporting a marginal PBT increase of +1% for FY25. Sanofi India retains market leadership in basal insulin (Lantus ~31% market share) and is investing to scale Soliqua and Toujeo via private and public sector access, while RWE and clinical work (LANDMARC, Soliqua Phase IV) provide evidence and KOL advocacy to support uptake and formulary inclusion across public programs and tier‑2/3 outreach. Corporate returns remain shareholder friendly: management proposed a dividend increase of ~5% versus prior year with EPS of INR 142 and a high payout ratio (~87%), reflecting a capital distribution stance supported by operational efficiency despite transitional top‑line headwinds.
Over the past 52 weeks, Sanofi India Ltd has traded between a low of ₹3,057.60 and a high of ₹5,104.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sanofi India Ltd has a market capitalization of approximately 7,092.89. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sanofi India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.64 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 7,092.89 Cr, Sanofi India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sanofi India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sanofi India Ltd is 19.64. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Sanofi reported Q2 2026 net sales growth of 17.8% at constant exchange rates (CER), with net sales of €11,597 million.
It disclosed an intimation confirming the publication of its unaudited financial results notice for the quarter and half-year ended June 30, 2026.
Revenue from operations for the quarter ended June 30, 2026 was ₹2,357 million (₹235.7 crore), up 7% year-on-year.
It informed exchanges about the publication and availability of its unaudited financial results for the quarter and half-year ended June 30, 2026, as a routine SEBI Regulation 30 compliance.
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
724.00 | 7,682 Cr | 54.20 | 6.44 | 0.14 | 10.82 | 16.48 | 9.50 | ||
826.90 | 7,516 Cr | 35.26 | 3.54 | 0.42 | 8.22 | 9.59 | 6.12 | ||
1133.55 | 7,283 Cr | 63.14 | 5.60 | 0.00 | 9.56 | 11.55 | — | ||
900.00 | 7,274 Cr | 36.67 | 6.07 | 0.11 | 17.46 | 23.00 | 14.62 | ||
3080.00 | 7,093 Cr | 19.64 | 8.59 | 3.99 | 39.20 | 51.99 | 23.01 | ||
1472.55 | 6,758 Cr | 51.66 | 7.24 | 0.00 | 12.36 | 14.43 | 8.16 | ||
1153.10 | 6,556 Cr | 42.56 | 6.01 | 0.17 | 12.92 | 14.30 | 8.38 | ||
| Median: 7 Co. | — | 1133.55 | 7,274 Cr | 42.56 | 6.07 | 0.14 | 12.36 | 14.43 | 8.94 |
Sanofi India Limited is a listed pharmaceutical company focused on manufacturing and marketing prescription medicines in India, with a strategic emphasis on diabetes care (insulin portfolio) and distribution partnerships for cardiovascular, CNS and oral anti‑diabetic categories; it operates manufacturing sites (notably Goa) and sells through independent distributors across domestic and select export markets.
The company completed a pivotal transformation in 2025: refocusing on insulin, launching a partnership model for legacy brands, and reorganizing around digital and AI‑enabled customer engagement, which management cites as the foundation for sustainable, profitable growth even as transitional effects impacted reported revenue and segmental comparability.
Financially the year shows mixed signals: domestic sales were essentially flat (+1% FY), diabetes insulin domestic volumes grew +6% and Q4 diabetes grew +11%, but exports plunged (-40% FY) driven by Ankleshwar divestment and partnership phasing, while operating expenses were cut ~17% year‑on‑year supporting a marginal PBT increase of +1% for FY25.
Sanofi India retains market leadership in basal insulin (Lantus ~31% market share) and is investing to scale Soliqua and Toujeo via private and public sector access, while RWE and clinical work (LANDMARC, Soliqua Phase IV) provide evidence and KOL advocacy to support uptake and formulary inclusion across public programs and tier‑2/3 outreach.
Corporate returns remain shareholder friendly: management proposed a dividend increase of ~5% versus prior year with EPS of INR 142 and a high payout ratio (~87%), reflecting a capital distribution stance supported by operational efficiency despite transitional top‑line headwinds.
Pharmaceuticals & Biotechnology
Pharmaceuticals
7,208 Cr
Low Risk
20.0
37.4
-3.7
8.6
5,104.70
3,057.60
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
5
Neutral
6
Bullish
3
Bearish
28
Neutral
6
Bullish
12
Bearish
23
Neutral
0
Bullish
9
Bearish
5
Neutral
6
Bullish
3
Bearish
5
Neutral
6
Bullish
3
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
